Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 107,117 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Study Clear all
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy

NCT07225556
View directory record Official record
Conditions
Overweight, Obesity
Interventions
LY4167586, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 22, 2026, 8:14 PM EDT
Completed Not applicable Interventional

Breast Cancer - Navigate - Prospective Cohort

NCT06271356
View directory record Official record
Conditions
Breast Cancer, Quality of Life, Chemotherapy
Interventions
BC-Navigate
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 22, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Safety, Efficacy and Cycle Control of a Contraceptive Vaginal Ring

NCT00455156
View directory record Official record
Conditions
Contraception
Interventions
150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR)
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
15
States / cities
Los Angeles, California • Denver, Colorado • Lexington, Kentucky + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 22, 2026, 8:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of MGL-3196 With Pioglitazone

NCT04671056
View directory record Official record
Conditions
Healthy
Interventions
MGL-3196, Pioglitazone 15mg
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 22, 2026, 8:14 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1

NCT06532656
View directory record Official record
Conditions
HIV-1-infection
Interventions
Lenacapavir, Bictegravir/Lenacapavir (BIC/LEN) FDC, Bictegravir/Lenacapavir
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
2 Years to 17 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 22, 2026, 8:14 PM EDT
Terminated Not applicable Interventional

A Study to Determine the Effectiveness of Endoscopic Full-Thickness Plication for the Treatment of GERD

NCT00575822
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
NDO Full-thickness Plicator, Sham Control
Device
Lead sponsor
NDO Surgical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
13
States / cities
Orange, California • San Ramon, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2008 · Synced Oct 22, 2026, 8:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The S.A.F.E. Study : Computer-Aided Counseling to Prevent Teen Pregnancy/Sexually Transmitted Diseases (STDs)

NCT00151151
View directory record Official record
Conditions
Pregnancy, Sexually Transmitted Diseases
Interventions
Computer-Assisted Motivational Intervention, Didactic Educational Counseling
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
13 Years to 21 Years · Female only
Enrollment
660 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 13, 2011 · Synced Oct 22, 2026, 8:14 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)

NCT07405151
View directory record Official record
Conditions
Oesophageal Squamous Cell Carcinoma
Interventions
I-DXd, Rescue Medication
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 22, 2026, 8:14 PM EDT
Completed Phase 1Phase 2 Interventional

Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C

NCT00593151
View directory record Official record
Conditions
Hepatitis C
Interventions
Locteron (controlled-release interferon alpha 2b), pegylated IFNa2b
Other · Biological
Lead sponsor
Biolex Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Detroit, Michigan • Dallas, Texas • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 22, 2026, 8:14 PM EDT
Recruiting Phase 4 Interventional

Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy

NCT05919329
View directory record Official record
Conditions
Castration Resistant Prostate Cancer, Castration Sensitive Prostate Cancer, Prostate Adenocarcinoma
Interventions
Piflufolastat, PSMA PET/CT Scan, PSMA PET/MRI scan, Biospecimen Collection, Electronic Health Record Review
Drug · Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 22, 2026, 8:14 PM EDT
Recruiting Not applicable Interventional

Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma

NCT06057051
View directory record Official record
Conditions
Glaucoma
Interventions
iStent Infinite
Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
35 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 22, 2026, 8:14 PM EDT
Recruiting Phase 3 Interventional

Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema

NCT07817251
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
CagriSema
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
40
States / cities
Gilbert, Arizona • Fountain Valley, California • Glendora, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 22, 2026, 8:14 PM EDT
Active, not recruiting Phase 2 Interventional

Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)

NCT05915351
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Pancreas Adenocarcinoma, Pancreas Cancer
Interventions
Enfortumab vedotin
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 22, 2026, 8:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

NCT01615029
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Part 1 (Dose Escalation): Daratumumab, Part 2 (Dose Expansion): Daratumumab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 22, 2026, 8:14 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

NCT05142696
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
[177Lu]Lu-DOTA-TATE, Atezolizumab, [68Ga]Ga-DOTA-TATE, Carboplatin, Etoposide
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
7
States / cities
Orlando, Florida • Athens, Georgia • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 22, 2026, 8:14 PM EDT
Completed Phase 1 Interventional Results available

Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities

NCT02985996
View directory record Official record
Conditions
HIV Infections
Interventions
Truvada, Genvoya
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 22, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD

NCT02451696
View directory record Official record
Conditions
Epilepsy, Tuberous Sclerosis Complex, Focal Cortical Dysplasia
Interventions
Everolimus
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
2 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 22, 2026, 8:14 PM EDT
Terminated Phase 2 Interventional Results available

Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy

NCT02946996
View directory record Official record
Conditions
Prostate Cancer
Interventions
Metformin, OPC
Drug · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 22, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU

NCT01889862
View directory record Official record
Conditions
Phenylketonuria (PKU)
Interventions
BMN165 20mg/day, BMN165 40mg/day, Placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years to 70 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
29
States / cities
La Jolla, California • Oakland, California • Aurora, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated May 21, 2021 · Synced Oct 22, 2026, 8:14 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001

NCT01224262
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine), LIQ001 (0.45mg), LIQ001 (1.8mg)
Biological
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Mar 1, 2013 · Synced Oct 22, 2026, 8:14 PM EDT
Enrolling by invitation Not applicable Interventional

Ready, Set, Go! A Physical Fitness Intervention for Children With Mobility Challenges

NCT04789746
View directory record Official record
Conditions
Cerebral Palsy, Myelomeningocele, Arthrogryposis, Motor Skills Disorders, Gross Motor Development Delay
Interventions
adapted Chicago Run running program
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
6 Years to 18 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Chicago Heights, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 22, 2026, 8:14 PM EDT
Terminated Phase 3 Interventional Results available

Carotid Occlusion Surgery Study

NCT00029146
View directory record Official record
Conditions
Stroke, Ischemic Attack, Transient, Cerebral Infarction
Interventions
extracranial-intracranial bypass surgery, best medical therapy
Procedure · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 85 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 27, 2012 · Synced Oct 22, 2026, 8:14 PM EDT
Terminated Phase 3 Interventional Results available

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids

NCT03194646
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Vilaprisan (BAY1002670), Standard of care
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
94
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 22, 2026, 8:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Compare Pharmacokinetics Of Dacomitinib (PF-00299804) Between Healthy Subjects And Subjects With Mild And Moderate Hepatic Impairment

NCT01571388
View directory record Official record
Conditions
Healthy, Otherwise Healthy Volunteers With Mild or Moderate Hepatic Dysfunction
Interventions
dacomitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 74 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
Anaheim, California • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 22, 2026, 8:14 PM EDT